This study differs from previous work on IGFBP-1 and cardiovascular disease because of the novelty of applying IGFBP-1 to MACE risk prediction in PAD patients specifically, which has not been undertaken previously [15]. The gene discussed is IGFBP1; the disease is peripheral arterial disease.